Search by Drug Name or NDC
NDC 00024-5841-01 ZALTRAP 200 mg/8mL Details
ZALTRAP 200 mg/8mL
ZALTRAP is a INTRAVENOUS SOLUTION, CONCENTRATE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by sanofi-aventis U.S. LLC. The primary component is AFLIBERCEPT.
MedlinePlus Drug Summary
Aflibercept injection is used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). It is also used to treat macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss), diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss), and diabetic retinopathy (damage to the eyes caused by diabetes). Aflibercept injection is in a class of medications called vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonists. It works by stopping abnormal blood vessel growth and leakage in the eye(s) that may cause vision loss in people with certain eye conditions.
Related Packages: 00024-5841-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Aflibercept Injection
Ziv-aflibercept injection is used in combination with other medications to treat cancer of the colon (large intestine) or rectum that has spread to other parts of the body. Ziv-aflibercept is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors.
Related Packages: 00024-5841-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ziv-aflibercept Injection
Product Information
| NDC | 00024-5841 |
|---|---|
| Product ID | 0024-5841_8e160898-1926-4079-963c-e447c17a2566 |
| Associated GPIs | 21335010102030 |
| GCN Sequence Number | 069781 |
| GCN Sequence Number Description | ziv-aflibercept VIAL 200 MG/8ML INTRAVEN |
| HIC3 | V3N |
| HIC3 Description | ANTINEOPLASTIC - VEGF-A,B AND PLGF INHIBITORS |
| GCN | 32989 |
| HICL Sequence Number | 040362 |
| HICL Sequence Number Description | ZIV-AFLIBERCEPT |
| Brand/Generic | Brand |
| Proprietary Name | ZALTRAP |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ziv-aflibercept |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION, CONCENTRATE |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | mg/8mL |
| Substance Name | AFLIBERCEPT |
| Labeler Name | sanofi-aventis U.S. LLC |
| Pharmaceutical Class | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125418 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00024-5841-01 (00024584101)
| NDC Package Code | 0024-5841-01 |
|---|---|
| Billing NDC | 00024584101 |
| Package | 1 VIAL in 1 CARTON (0024-5841-01) / 8 mL in 1 VIAL |
| Marketing Start Date | 2012-08-03 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |